持续给予β-肾上腺素受体拮抗剂对安替比林和苯妥英清除率的差异影响。
Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.
作者信息
Perrild H, Kayser L, Poulsen H E, Skovsted L, Jørgensen B, Hansen J M
机构信息
Department of Medicine, F. Herlev Hospital, Denmark.
出版信息
Br J Clin Pharmacol. 1989 Nov;28(5):551-4. doi: 10.1111/j.1365-2125.1989.tb03541.x.
Abstract
- Antipyrine (1000 mg orally) clearance was studied 3 days before treatment with either atenolol (50 mg twice daily), metoprolol (100 mg twice daily), propranolol (80 mg twice daily) or placebo, and at day 5 and 18 during treatment. Phenytoin (100 mg intravenously) clearance was measured on days 0, 7 and 21 during treatment. 2. Antipyrine clearance was decreased by about 20% after 5 days of treatment with either propranolol or atenolol and this decrease persisted after 18 days of treatment. Antipyrine clearance did not change during treatment with either metoprolol or placebo. Phenytoin clearance did not change during any of the treatments.
摘要
- 在使用阿替洛尔（每日两次，每次50毫克）、美托洛尔（每日两次，每次100毫克）、普萘洛尔（每日两次，每次80毫克）或安慰剂治疗前3天以及治疗期间的第5天和第18天，研究了安替比林（口服1000毫克）清除率。在治疗期间的第0天、第7天和第21天测量苯妥英（静脉注射100毫克）清除率。2. 使用普萘洛尔或阿替洛尔治疗5天后，安替比林清除率降低约20%，且这种降低在治疗18天后持续存在。使用美托洛尔或安慰剂治疗期间，安替比林清除率未发生变化。在任何治疗期间，苯妥英清除率均未发生变化。
相似文献
1
Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.
Br J Clin Pharmacol. 1989 Nov;28(5):551-4. doi: 10.1111/j.1365-2125.1989.tb03541.x.
2
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.
Br J Clin Pharmacol. 1981 Dec;12(6):779-84. doi: 10.1111/j.1365-2125.1981.tb01306.x.
3
Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat.
J Pharmacol Exp Ther. 1990 Jul;254(1):116-22.
4
Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.
Br J Clin Pharmacol. 2001 Jul;52(1):69-76. doi: 10.1046/j.0306-5251.2001.01417.x.
5
Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):29S-35S. doi: 10.1111/j.1365-2125.1984.tb02425.x.
6
Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine.
Br J Clin Pharmacol. 1984 Dec;18(6):853-60. doi: 10.1111/j.1365-2125.1984.tb02555.x.
7
The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects.
Br J Clin Pharmacol. 1982 Jun;13(6):817-20. doi: 10.1111/j.1365-2125.1982.tb01872.x.
8
Central propranolol and pindolol, but not atenolol nor metoprolol, inhibit sexual behavior in male rats.
Physiol Behav. 1996 Feb;59(2):241-6. doi: 10.1016/0031-9384(95)02128-0.
9
Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol.
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):37S-44S. doi: 10.1111/j.1365-2125.1984.tb02426.x.
10
Interaction between the beta-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism.
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):65S-68S. doi: 10.1111/j.1365-2125.1984.tb02430.x.
引用本文的文献
1
Clinical and pharmacological factors influencing serum clozapine and norclozapine levels.
Front Pharmacol. 2024 Mar 27;15:1356813. doi: 10.3389/fphar.2024.1356813. eCollection 2024.
2
Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.
J Neural Transm (Vienna). 2015 Nov;122(11):1609-17. doi: 10.1007/s00702-015-1403-7. Epub 2015 May 5.
3
The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.
Br J Clin Pharmacol. 1990 Oct;30(4):638-43. doi: 10.1111/j.1365-2125.1990.tb03827.x.
本文引用的文献
1
Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
Clin Pharmacol Ther. 1981 Apr;29(4):493-7. doi: 10.1038/clpt.1981.68.
2
Lack of effect of atenolol on antipyrine clearance.
Br J Clin Pharmacol. 1982 Nov;14(5):743-4. doi: 10.1111/j.1365-2125.1982.tb04967.x.
3
The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects.
Br J Clin Pharmacol. 1982 Jun;13(6):817-20. doi: 10.1111/j.1365-2125.1982.tb01872.x.
4
Optimal sampling times for minimum variance of clearance determination.
Br J Clin Pharmacol. 1983 Feb;15(2):231-5. doi: 10.1111/j.1365-2125.1983.tb01491.x.
5
Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism.
Eur J Clin Pharmacol. 1983;25(2):215-22. doi: 10.1007/BF00543794.
6
A one-sample method for antipyrine clearance determination in rats.
Pharmacology. 1984;29(2):110-6. doi: 10.1159/000137999.
7
Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism.
Clin Endocrinol (Oxf). 1983 Feb;18(2):139-42. doi: 10.1111/j.1365-2265.1983.tb03196.x.
8
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists.
Br J Clin Pharmacol. 1981 Dec;12(6):779-84. doi: 10.1111/j.1365-2125.1981.tb01306.x.
9
Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism.
Epilepsia. 1968 Mar;9(1):17-22. doi: 10.1111/j.1528-1157.1968.tb04954.x.
10
Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man.
Br J Clin Pharmacol. 1985 May;19(5):593-6. doi: 10.1111/j.1365-2125.1985.tb02685.x.
Zotero 插件